NEW YORK, July 22, 2011 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins E. Kevin Hrusovsky, President & CEO, Caliper Life Sciences Inc (CALP) to discuss the company's industry, strategy, financials and positioning.
Click here to view video:
Kevin Hrusovsky, President & CEO:
E. Kevin Hrusovsky was appointed President and CEO of Caliper Life Sciences when Zymark Corporation was acquired by Caliper in July 2003. Prior to the acquisition, he served as President and CEO for Zymark starting in late 1996, where he successfully transformed Zymark from a custom robotics company into a formidable Life Sciences "Tools" company. Caliper (CALP) stock price has increased 150% each of the past two years, making CALP one of the fastest growing life science tools providers on Wall Street. From 1992 to 1996, he was Director of International Business, Agricultural Chemical Division, and President of the Pharmaceutical Division, for FMC Corporation. From 1983 to 1992, he held several management positions at E.I. DuPont de Nemours, including North American Sales and Marketing Head, Teflon.
Hrusovsky currently sits on Caliper's Board of Directors, SeraCare's Board of Directors, the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children's Hospital Boston. He formerly served on Xenogen Corporation's Board of Directors. Hrusovsky received an Honorary Doctorate degree from Framingham State University for contributions to life sciences. He received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University. He and his family are authentic Buckeyes!
About Caliper Life Science Inc:
Caliper is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839